ESPR - Company ID 0001434868
The table below shows Esperion Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $80.10M | $87.31M | $82.39M | $65.00M | $51.63M | $73.83M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Esperion Therapeutics, Inc. reported annual revenue of $403.13M for fiscal year 2025. That is up 21.3% from $332.31M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $43.12M |
| $41.85M |
| $39.51M |
| $43.00M |
| $39.98M |
| $44.19M |
| Operating income | -$6.58M | -$9.96M | $7.09M | -$22.10M | -$16.03M | $2.58M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$25.20M | -$31.33M | -$12.72M | -$40.45M | -$29.52M | -$61.92M |
| EPS (diluted) | -$0.10 | -$0.16 | -$0.06 | -$0.21 | -$0.15 | -$0.33 |